December 19, 2025

Abbreviated Azacitidine Regimen Improves Outcomes in Lower-Risk MDS

A multicenter trial led by investigators at The University of Texas MD Anderson Cancer Center demonstrated that a 5-day regimen of azacitidine provides the best balance of efficacy and safety for pati...

The ASCO Post

December 18, 2025

Short-Term Pain Reduction for CRPS

Bisphosphonates may reduce CRPS pain intensity in the short term, although treatment is likely accompanied by adverse events.

Conexiant

December 18, 2025

Psychiatric Genetics: Shared Risk Across Disorders

Large-scale genomic analysis of 14 psychiatric disorders identified five underlying genetic factors and biological pathways

Conexiant

December 18, 2025

New Approach Methodologies: Why the Future of Drug Development Must Be Human

NAMs aren’t just a scientific upgrade, but a moral and practical necessity. The tools are ready. The question is: does the industry have the will to use them?

The Medicine Maker

December 17, 2025

Bridging the Digital Divide: How Collaboration and Standardization Are Shaping the Future of Biotech

The promise of cell and gene therapy is boundless, but data silos are holding it back. Standardization, interoperability, and collaboration can move data as freely as science itself.

The Medicine Maker

December 17, 2025

Promising Data For Off-the-Shelf Gene-edited Cell Therapy

New clinical results outline patient responses to a donor-derived, gene-edited cell therapy in relapsed and refractory T-cell leukemia

The Medicine Maker

December 16, 2025

Flipped Nivolumab/Ipilimumab Dosing Improves Responses, Survival, and Safety in Advanced Melanoma

The flipped dose for nivolumab 3 mg/kg and ipilimumab 1 mg/kg led to improved response rates and survival findings as well as lower severe immune-related toxicities compared with the standard dose of ...

The ASCO Post

December 15, 2025

BTX Injections Appear Safe for Refractory Digital Ischemia in Systemic Sclerosis

Botulinum toxin injections show strong safety and efficacy as an adjunctive treatment for refractory digital ischemia, ulcers, and gangrene in patients with systemic sclerosis, according to a new JAMA Dermatology meta-analysis.

Conexiant

December 12, 2025

Autism's 3-Hit Model Targets Mitochondria

Three necessary metabolic disruptions converge on cell danger response, suggesting prevention opportunities.

Conexiant